Drug Trial Radar · NCT02550067
The Evidence for Contraceptive Options and HIV Outcomes Trial
Last checked: Nov 19, 2026Latest source record: Aug 20, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,830
Actual
Start
Dec 14, 2015
Primary completion
Oct 31, 2018
Study completion Oct 31, 2018
Sponsor
- Lead sponsor
- FHI 360Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Washington; Wits Reproductive Health and HIV Institute; World Health Organization; Madibeng Centre for Research; Maternal Adolescent and Child Health Research; Qhakaza Mbokodo Research Clinic; The Aurum Institute NPC; Effective Care Research Unit; Emavundleni Research Centre; Setshaba Research Centre; University of North Carolina, Chapel Hill; Family Life Association of Swaziland; Columbia University; Kenya Medical Research Institute
- First posted
- Sep 15, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- Who can join
- Female only, from 16 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The ECHO Study is an open-label randomized clinical trial that will compare three highly effective, reversible methods of contraception (including a non-hormonal method) to evaluate whether there is a link between use of any of these methods and increased risk of acquiring HIV infection. A randomized clinical trial among about 7,800 women in four countries, ECHO will deliver evidence to support and guide individual, policy and programmatic decisions on contraception for women at risk of acquiring HIV infection.
Conditions
- HIV
- Contraception
Interventions
DMPADrug
Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
LNGDrug
Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
Copper IUDDrug
Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare risks of HIV acquisition between women randomized to DMPA, LNG and copper IUDTime frame: From enrollment to 18 months
Locations
12 sites in 4 countries. Site status is shown where the registry gives one.
FLAS/ICAP Clinic 1& Clinic 2
Manzini, Eswatini
Kisumu East Research Care and Training Program
Kisumu, Kenya
Madibeng Centre for Research
Brits, South Africa
Emavundleni Research Centre
Cape Town, South Africa
MatCH Research Unit Commercial City
Durban, South Africa
Effective Care Research Unit (ECRU) Frere Maternity Hospital
East London, South Africa
Wits Reproductive Health and HIV Institute (WRHI)
Johannesburg, South Africa
Aurum Klerksdorp Gavin Churchyard Legacy Centre
Klerksdorp, South Africa
QM ladysmith
Ladysmith, South Africa
MatCH Research Unit Edendale
Pietermaritzburg, South Africa
Setshaba Research Centre
Soshanguve, South Africa
University Teaching Hospital, Lusaka, Zambia
Lusaka, Zambia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.